Literature DB >> 21153565

Mutation analysis of the PALB2 cancer predisposition gene in familial melanoma.

N Sabbaghian1, R Kyle, A Hao, D Hogg, M Tischkowitz.   

Abstract

PALB2 is a breast and pancreas cancer susceptibility gene whose protein is closely associated with BRCA2 and is essential for BRCA2 anchorage to nuclear structures. This functional relationship made PALB2 a candidate gene for susceptibility to BRCA2-related cancers such as melanoma. The purpose of this study was to screen for the presence of germline mutations in PALB2 in familial melanoma cases. We sequenced the exons and intron-exon boundaries of PALB2 in probands from 53 families with familial melanoma where CDKN2A mutations were absent. A number of previously reported coding and non-coding variants were observed. However, no truncating mutations were identified. These results indicate that deleterious PALB2 mutations are unlikely to play a significant role in familial melanoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21153565     DOI: 10.1007/s10689-010-9405-y

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  10 in total

1.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

Authors:  Bing Xia; Qing Sheng; Koji Nakanishi; Akihiro Ohashi; Jianmin Wu; Nicole Christ; Xinggang Liu; Maria Jasin; Fergus J Couch; David M Livingston
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

2.  High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Elizabeth M Gillanders; Nicholas K Hayward; Marie-Francoise Avril; Esther Azizi; Giovanna Bianchi-Scarra; D Timothy Bishop; Brigitte Bressac-de Paillerets; William Bruno; Donato Calista; Lisa A Cannon Albright; Florence Demenais; David E Elder; Paola Ghiorzo; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M Mackie; Veronica Magnusson; Graham J Mann; Kristin Niendorf; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Femke A de Snoo; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

3.  Germline p16 mutations in familial melanoma.

Authors:  C J Hussussian; J P Struewing; A M Goldstein; P A Higgins; D S Ally; M D Sheahan; W H Clark; M A Tucker; N C Dracopoli
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

4.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

Review 5.  PALB2/FANCN: recombining cancer and Fanconi anemia.

Authors:  Marc Tischkowitz; Bing Xia
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

6.  BRCA1 and BRCA2 families and the risk of skin cancer.

Authors:  Ophira M Ginsburg; Charmaine Kim-Sing; William D Foulkes; Parviz Ghadirian; Henry T Lynch; Ping Sun; Steven A Narod
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

Review 7.  BRCA1 and BRCA2: 1994 and beyond.

Authors:  Steven A Narod; William D Foulkes
Journal:  Nat Rev Cancer       Date:  2004-09       Impact factor: 60.716

Review 8.  Genetic risk factors for melanoma.

Authors:  Kathrine Damm Meyle; Per Guldberg
Journal:  Hum Genet       Date:  2009-07-08       Impact factor: 4.132

9.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

10.  Analysis of PALB2/FANCN-associated breast cancer families.

Authors:  Marc Tischkowitz; Bing Xia; Nelly Sabbaghian; Jorge S Reis-Filho; Nancy Hamel; Guilan Li; Erik H van Beers; Lili Li; Tayma Khalil; Louise A Quenneville; Atilla Omeroglu; Aletta Poll; Pierre Lepage; Nora Wong; Petra M Nederlof; Alan Ashworth; Patricia N Tonin; Steven A Narod; David M Livingston; William D Foulkes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-09       Impact factor: 11.205

  10 in total
  4 in total

1.  Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.

Authors:  Xiaohong R Yang; Lea Jessop; Timothy Myers; Laufey Amundadottir; Ruth M Pfeiffer; William Wheeler; Kristen M Pike; Jeff Yuenger; Laurie Burdett; Meredith Yeager; Stephen J Chanock; Margaret A Tucker; Alisa M Goldstein
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

2.  Analysis of the miR-34a locus in 62 patients with familial cutaneous melanoma negative for CDKN2A/CDK4 screening.

Authors:  Angela M Cozzolino; Lucia Pedace; Marco Castori; Paola De Simone; Nicoletta Preziosi; Isabella Sperduti; Chiara Panetta; Valerio Mogini; Carmelilia De Bernardo; Aldo Morrone; Caterina Catricalà; Paola Grammatico
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

3.  Assessment of PALB2 as a candidate melanoma susceptibility gene.

Authors:  Lauren G Aoude; Mai Xu; Zhen Zhen Zhao; Michael Kovacs; Jane M Palmer; Peter Johansson; Judith Symmons; Jeffrey M Trent; Nicholas G Martin; Grant W Montgomery; Kevin M Brown; Nicholas K Hayward
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

4.  Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada.

Authors:  Taila Hartley; Luca Cavallone; Nelly Sabbaghian; Rachel Silva-Smith; Nancy Hamel; Olga Aleynikova; Erika Smith; Valerie Hastings; Pedro Pinto; Marc Tischkowitz; Eva Tomiak; William D Foulkes
Journal:  Hered Cancer Clin Pract       Date:  2014-08-28       Impact factor: 2.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.